Teva Pharmaceutical Industries (TEVA) Income from Non-Controlling Interests (2009 - 2025)

Teva Pharmaceutical Industries (TEVA) has 17 years of Income from Non-Controlling Interests data on file, last reported at $1.0 million in Q3 2025.

• Quarterly Income from Non-Controlling Interests fell 97.87% year-over-year to $1.0 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $7.0 million (up 102.19% YoY) and the FY2025 annual result came in at $7.0 million, up 102.19% from the prior year.
• Income from Non-Controlling Interests retreated to $1.0 million in Q3 2025, from $6.0 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $47.0 million in Q3 2024 to a low of -$280.0 million in Q1 2024.
• A 5-year average of -$21.3 million and a median of $3.0 million in 2022 frame the typical range for Income from Non-Controlling Interests.
• The widest YoY moves for Income from Non-Controlling Interests: up 487.5% in 2024, down 1550.0% in 2024.
• Tracing TEVA's Income from Non-Controlling Interests over 5 years: stood at $7.0 million in 2021, then plunged by 557.14% to -$32.0 million in 2022, then soared by 112.5% to $4.0 million in 2023, then slumped by 1550.0% to -$58.0 million in 2024, then soared by 101.72% to $1.0 million in 2025.
• The last three Income from Non-Controlling Interests figures came in at $1.0 million (Q3 2025), $6.0 million (Q1 2025), and -$58.0 million (Q4 2024), per Business Quant data.